Register | Login
The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
NEWS
CONFERENCES
VIDEOS
Case-Based Peer Perspectives
Expert Perspective Virtual Tumor Board
Interviews
Investigator Perspectives
Precision Medicine
PUBLICATIONS
Evolving Paradigms
Targeted Therapies in Oncology
The Journal of Targeted Therapies in Cancer
ONCAlert | Upfront Therapy for mRCC

Specialties >>

AML
Biosimilars
Bladder Cancer
Brain Cancer
Breast Cancer
CLL
Colorectal Cancer
DLBCL
EGFR+ Lung Cancer
Follicular Lymphoma
Gastric Cancer
Genitourinary Cancers
GI Cancers
Gynecologic Cancers
HCC
Head & Neck Cancers
Hematology
HER2-Negative Breast Cancer
Immunotherapy
Lung Cancer
Lymphomas
Mantle Cell Lymphoma
Melanoma
MPNs
Multiple Myeloma
Ovarian Cancer
Prostate Cancer
Renal Cell Carcinoma
Sarcoma
Skin Cancers
Thyroid Cancers

Partners >>

Dialogues in Diagnostics
Differential Diagnosis
Case-Based Peer Perspectives
Email Sign-Up
Publications  >  Evolving Paradigms  >  2017  >  Non-Small Cell Lung Cancer  >  

Dr. Langer Discusses Current Treatment Strategies for Patients With Non-Driver Nonsquamous NSCLC

Corey J. Langer, MD
Published Online: Sep 12,2017

Corey J. Langer, MD, Perelman Center for Advanced Medicine, Hospital of the University of Pennsylvania, discusses current treatment strategies for patients with non-driver nonsquamous non-small cell lung cancer (NSCLC).


Clinical Articles

Therapeutic Options Developing for Nondriver NSCLC, But Challenges Remain
Nonbiomarker NSCLC Population a Challenging Obstacle, Expert Says
Nonbiomarker, Nonsquamous NSCLC: Diagnosis, Statistics, Staging, and Testing
Current Treatment Strategies in Nonbiomarker Nonsquamous NSCLC
Emerging Treatment Strategies in Nonsquamous NSCLC
Dr. Bazhenova on the Treatment Landscape of Non-Driver NSCLC
Dr. Bazhenova on Remaining Challenges and Future Treatment Landscape of Non-Driver NSCLC
Dr. Bazhenova on Potential Impact of Immunotherapy in Non-Driver NSCLC
Dr. Bazhenova on Considering Factors to Treat Non-Driver Patients With NSCLC With Bevacizumab
Dr. Bazhenova on Current Treatment Strategies for Patients With Nonsquamous NSCLC
Dr. Bazhenova on the Prevalence of Patients With Non-Driver NSCLC
Dr. Langer Discusses Remaining Challenges With the Non-Driver NSCLC Population
Dr. Langer Discusses Ongoing Clinical Trials for Patients With Non-Driver NSCLC
Dr. Langer Discusses Current Treatment Strategies for Patients With Non-Driver Nonsquamous NSCLC
Dr. Langer Discusses the Prevalence of Patients With Non-Driver NSCLC
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.